HOME >> MEDICINE >> NEWS
Phase II trial of anthrax vaccine to begin

Center for Vaccine Research needs volunteers for Phase II Trial of anthrax vaccine candidate

(Torrance, CA April 22, 2004) The UCLA Center for Vaccine Research, a leading research program at the Research and Education Institute (REI) at Harbor UCLA Medical Center, announced today that it has initiated a Phase II trial of a new anthrax vaccine, rPA102 (VaxGen, Inc.). The 13-month trial is taking place at 12 medical centers in the United States and is one of two studies of rPA102 initiated this year under a multi-year, $80.3 million U.S. government contract to VaxGen, Inc. from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

VaxGen, Inc. began developing rPA102 to address the need for an anthrax vaccine that has an improved safety profile and a more practical dosing schedule compared to the existing licensed anthrax vaccine. rPA is a synthetic protein vaccine that induces antibodies that are designed to prevent illness by neutralizing anthrax toxins. rPA102 cannot cause anthrax infection. The goal of this study is to determine the optimal formulation of the rPA vaccine that will provide an early and protective immune response.

Healthy adults, 18 to 55 years of age, who have not received an anthrax vaccine and have not been exposed to anthrax, are needed to participate in this study. Participants will need to be available for 14 visits to the clinic (Torrance) over a one-year period. Participants will be compensated up to $700 for completion of study visits.

For further information on how to take part in this trial, please call 1-800-637-8860.


'"/>

Contact: Susan Partridge, BSN, MBA
partridge@humc.edu
310-781-3630
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
22-Apr-2004


Page: 1

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
3. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
4. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
5. Penn researchers announce results of Phase I trial using combretastatin drug
6. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
7. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
8. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
9. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
10. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer
11. Positive Results Of Pivotal Phase III Trial With ENBREL In Patients With Early, Active Rheumatoid Arthritis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/2/2018)... (PRWEB) , ... September 01, ... ... Mammography is proud to add HydraFacial MD® Elite to its leading menu ... uses patented, vortex-suction technology and an infusion of clinically-proven ingredients to dramatically ...
(Date:9/1/2018)... ... August 31, 2018 , ... SignatureCare Emergency Center is ... for the Fall semester to a deserving student. Get your applications in now as ... was awarded to Hanna Wu who is a medical student at Texas Southern University. ...
(Date:8/31/2018)... , ... August 31, 2018 , ... ... | 2018" list. , This list includes independent community hospitals as well as ... others care for small communities outside of large cities. The hospitals continue to ...
(Date:8/31/2018)... ... 31, 2018 , ... The social impact documentary feature film on homelessness, OFF ... NIH-funded researcher Luciana Lagana, aka Dr. Luciana, has been faring well at film ... Film Festival, IndieFEST Film Awards, Shawna Shea Memorial Film Festival, and Top Indie Film ...
(Date:8/31/2018)... ... August 31, 2018 , ... Rudina Thanasi, a scientifically validated ... energy treated nutraceutical to improve overall immunity and to combat inflammatory and autoimmune ... well as, inflammation. The following data was reported:,     Over ...
Breaking Medicine News(10 mins):
(Date:9/15/2018)... Calif. (PRWEB) , ... September ... ... phage display for molecular evolution incorporate deep sequencing to enable greater library ... construction and biophysical follow-up of potential hits remain. , Multiplexed phage display ...
(Date:9/13/2018)... (PRWEB) , ... September 13, 2018 , ... The ultimate ... Located at 31-57 31st St., the new arrival is called Form50 Fitness . ... by Sebastien Lagree called The Megaformer™ - a hybrid Pilates reformer with pulleys, weights, ...
(Date:9/13/2018)... ... September 13, 2018 , ... NCPDP announced today that its ... correct implementation of the NCPDP SCRIPT Standard Version 2017071 ahead of the January ... identified by the industry as vital enhancements in improving patient safety, clinical decision-making, ...
Breaking Medicine Technology:
Cached News: